Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours

[1] Demicheli R(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 1341-1352

[2] Ardoino I(2010)Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast BMC Cancer 10 656-1846

[3] Boracchi P(2017)20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years N Engl J Med 377 1836-15905

[4] Coradini D(2003)Gene expression profiles of primary breast tumors maintained in distant metastases Proc Natl Acad Sci U S A 100 15901-37184

[5] Agresti R(2015)Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing Oncotarget 6 37169-430

[6] Ferraris C(2016)Molecular concordance between primary breast cancer and matched metastases Breast J 22 420-137

[7] Pan HC(1998)Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? Breast Cancer Res Treat 51 133-12400

[8] Gray R(2011)Controversies in clinical cancer dormancy Proc Natl Acad Sci U S A 108 12396-622

[9] Braybrooke J(2014)Mechanisms of disseminated cancer cell dormancy: an awakening field Nat Rev Cancer 14 611-82

[10] Davies C(2017)Mechanisms governing metastatic dormancy in breast cancer Semin Cancer Biol 44 72-234

[1] Demicheli R(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 1341-1352

[2] Ardoino I(2010)Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast BMC Cancer 10 656-1846

[3] Boracchi P(2017)20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years N Engl J Med 377 1836-15905

[4] Coradini D(2003)Gene expression profiles of primary breast tumors maintained in distant metastases Proc Natl Acad Sci U S A 100 15901-37184

[5] Agresti R(2015)Remarkable similarities of chromosomal rearrangements between primary human breast cancers and matched distant metastases as revealed by whole-genome sequencing Oncotarget 6 37169-430

[6] Ferraris C(2016)Molecular concordance between primary breast cancer and matched metastases Breast J 22 420-137

[7] Pan HC(1998)Estimate of tumor growth time for breast cancer local recurrences: rapid growth after wake-up? Breast Cancer Res Treat 51 133-12400

[8] Gray R(2011)Controversies in clinical cancer dormancy Proc Natl Acad Sci U S A 108 12396-622

[9] Braybrooke J(2014)Mechanisms of disseminated cancer cell dormancy: an awakening field Nat Rev Cancer 14 611-82

[10] Davies C(2017)Mechanisms governing metastatic dormancy in breast cancer Semin Cancer Biol 44 72-234